系统性血管炎合并COVID-19重症结局的危险因素:一项基于注册登记的双国队列研究
该多中心队列研究纳入英国和爱尔兰血管炎注册中心 affiliated 的65例系统性血管炎合并COVID-19患者,评估重症结局(需高级氧疗、有创通气或死亡)的危险因素。结果显示38%患者发生重症结局,背景糖皮质激素治疗(调整OR 3.7,95%CI 1.1-14.9,P=0.047)和合并呼吸系统疾病(调整OR 7.5,95%CI 1.9-38.2,P=0.006)与重症结局相关,而血管炎疾病活动度和非糖皮质激素免疫抑制治疗未显示关联。
要点
- 系统性血管炎合并COVID-19患者中38%发生重症结局,28%死亡。
- 背景糖皮质激素治疗与重症COVID-19结局独立相关(调整OR 3.7)。
- 合并呼吸系统疾病与重症结局强相关(调整OR 7.5)。
核心结论
- 在系统性血管炎患者中,COVID-19就诊时使用糖皮质激素和合并呼吸系统疾病与重症结局相关。
研究设计与样本
- 多中心队列研究,通过英国和爱尔兰国家血管炎注册中心 affiliated 的中心参与,纳入65例系统性血管炎合并COVID-19患者。
主要发现
- 65例患者中位年龄70岁,49%为女性,25例(38%)发生重症结局。
- 55例(85%)为ANCA相关性血管炎(AAV),59例(91%)需住院,7例(11%)入住ICU,18例(28%)死亡。
- 背景糖皮质激素治疗与重症结局相关(调整OR 3.7,95%CI 1.1-14.9,P=0.047)。
- 合并呼吸系统疾病与重症结局相关(调整OR 7.5,95%CI 1.9-38.2,P=0.006)。
- 血管炎疾病活动度和非糖皮质激素免疫抑制治疗与重症结局无关联。
关键数值与推荐
- 重症COVID-19结局定义为需要高级氧疗、需要有创通气或死亡。
临床怎么用
- 对于系统性血管炎患者,临床决策时应考虑就诊时糖皮质激素使用和合并呼吸系统疾病对重症COVID-19风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: COVID-19 is a novel infectious disease with a broad spectrum of clinical severity. Patients with systemic vasculitis have an increased risk of serious infections and may be at risk of severe outcomes following COVID-19. We undertook this study to establish the risk factors for severe COVID-19 outcomes in these patients, including the impact of immunosuppressive therapies. METHODS: A multicenter cohort was developed through the participation of centers affiliated with national UK and Ireland vasculitis registries. Clinical characteristics and outcomes are described. Logistic regression was used to evaluate associations between potential risk factors and a severe COVID-19 outcome, defined as a requirement for advanced oxygen therapy, a requirement for invasive ventilation, or death. RESULTS: The cohort included 65 patients with systemic vasculitis who developed COVID-19 (median age 70 years, 49% women), of whom 25 patients (38%) experienced a severe outcome. Most patients (55 of 65 [85%]) had antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Almost all patients required hospitalization (59 of 65 [91%]), 7 patients (11%) were admitted to intensive care, and 18 patients (28%) died. Background glucocorticoid therapy was associated with severe outcomes (adjusted odds ratio [OR] 3.7 [95% confidence interval 1.1-14.9]; P = 0.047), as was comorbid respiratory disease (adjusted OR 7.5 [95% confidence interval 1.9-38.2]; P = 0.006). Vasculitis disease activity and nonglucocorticoid immunosuppressive therapy were not associated with severe outcomes. CONCLUSION: In patients with systemic vasculitis, glucocorticoid use at presentation and comorbid respiratory disease were associated with severe outcomes in COVID-19. These data can inform clinical decision-making relating to the risk of severe COVID-19 in this vulnerable patient group.
引用
- Rutherford MA, Scott J, Karabayas M, et al. Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. Arthritis Rheumatol. 2021. PMID: 33750043. doi:10.1002/art.41728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。